Comparative Pharmacology
Head-to-head clinical analysis: TETRACAINE HYDROCHLORIDE versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACAINE HYDROCHLORIDE versus XYLOCAINE 5 W GLUCOSE 7 5.
TETRACAINE HYDROCHLORIDE vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracaine hydrochloride is a local anesthetic of the ester type that reversibly blocks nerve conduction by decreasing sodium ion permeability across the neuronal membrane, thereby stabilizing the membrane and preventing the initiation and transmission of nerve impulses.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Topical: 0.5-2% solution or ointment applied to affected area up to 4 times daily as needed. Maximum single dose: 20 mL of 2% solution (400 mg). Spinal anesthesia: 0.5% solution, 2-3 mL (10-15 mg) injected intrathecally.
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–3 minutes in plasma due to rapid hydrolysis; clinical effect duration is dose-dependent (15–30 minutes for topical anesthesia).
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Primarily metabolized by plasma pseudocholinesterase; renal excretion of metabolites accounts for >95% of elimination, with <2% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic